Get started
Author

Márk Plander

Observed names: M Plander, M. Plander, Mark Plander, Márk Béla Plander, Plander, Mark, Plander, Márk
ORCID: 0000-0002-5591-8340
Observed ORCID: 0000-0002-5591-8340
OpenAlex ID: A5074843807
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
2023 · Srdan Verstovsek, Aaron T Gerds, et al. · The Lancet · 224
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation
2007 · G. Brockhoff, B. Heckel, et al. · Cell Proliferation · 89
PDF
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
2009 · M Plander, S Seegers, et al. · Leukemia · 72
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
2019 · Szilvia Lovas, Gergely Varga, et al. · International Journal of Hematology · 31
PDF
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
2023 · Lili Kotmayer, Tamás László, et al. · International Journal of Molecular Sciences · 29
PDF
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
2019 · Gergely Varga, Zsolt Nagy, et al. · Pathology & Oncology Research · 29
PDF
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms
2018 · Ambrus Gángó, Réka Mózes, et al. · Leukemia Research · 28
Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma
2011 · Márk Plander, Peter Ugocsai, et al. · Annals of Hematology · 28
Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy
2021 · Csaba Bödör, Lili Kotmayer, et al. · British Journal of Haematology · 21
PDF
Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment
2015 · Mark Plander, Tamás Szendrei, et al. · Annals of Hematology · 19
Optimization of three‐ and four‐color multiparameter DNA analysis in lymphoma specimens
2003 · M. Plander, G. Brockhoff, et al. · Cytometry Part A · 19
PDF
In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment
2018 · Csilla Kriston, Márk Plander, et al. · Annals of Hematology · 13
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
2023 · Ákos Nagy, Bence Bátai, et al. · Journal of Internal Medicine · 12
PDF
Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia
2011 · János László Iványi, Éva Marton, et al. · Orvosi Hetilap · 10
Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome
2018 · Mark Plander, Tamás Szendrei, et al. · Pathology & Oncology Research · 9
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
2022 · Ferenc Takács, Lili Kotmayer, et al. · Pathology & Oncology Research · 8
PDF
Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation
2023 · Tamás László, Lili Kotmayer, et al. · The Journal of Pathology Clinical Research · 7
PDF
A TP53-mutáció-analízis jelentősége krónikus lymphocytás leukaemiában
2017 · Viktória Fésüs, Dóra Marosvári, et al. · Orvosi Hetilap · 7
Rare autoimmune disorders with Mendelian inheritance
2016 · Mark Plander, Bernadette Kalman · Autoimmunity · 6
Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes
2024 · Márk Plander, Mária Kányási, et al. · Pathology & Oncology Research · 5
PDF
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy
2025 · Tamás László, László Imre Pinczés, et al. · The Journal of Pathology · 4
PDF
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia
2021 · Csilla Kriston, Márk Hernádfői, et al. · Hematological Oncology · 4
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
2022 · Szilvia Lovas, Nóra Obajed Al-Ali, et al. · Pathology & Oncology Research · 3
PDF
T-sejtes nagy granuláris lymphocytás leukémia ezer arca és sikeres kezelése
2022 · Szilamér Kovács, Zsuzsanna Szabó, et al. · Hematológia–Transzfuziológia · 2
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
2021 · Gergely Varga, András Dávid Tóth, et al. · Pathology & Oncology Research · 2
PDF
Works count: 54
Citation count: 685
H-index: 12
I10-index: 14
Year
Topic
Type